Cruz CSD,Tanoue LT,Matthay RA .2011 .Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med, 32(4) : 605-44.
Glatzel-Plucinska N,Piotrowska A,Grzegrzolka J,Olbromski M,Rzechonek A,Dziegiel P .2018 .SATB1 level correlates with Ki-67 expression and is a positive prognostic factor in non-small cell lung carcinoma. Anticancer Res, 38(2) : 723-36.
Kanitkar AA,Schwartz AG,George J,Soubani AO .2018 .Causes of death in long-term survivors of non-small cell lung cancer: A regional Surveillance, Epidemiology, and End Results study. Ann Thorac Med, 13(2) : 76-81.
Konishi J,Yamazaki K,Azuma M,Kinoshita I,Dosaka-Akita H,Nishimura M. .2004 .B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res, 10(15) : 5094-100.
Sheppard KA,Fitz LJ,Lee JM,Benander C,George JA,Wooters J .2004 .PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ. FEBS Lett, 574(1- 3) : 37-41.
Parra ER,Villalobos P,Mino B,Rodriguez-Canales J .2018 .Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol, 26(2) : 83-93.
Pardoll DM .2012 .The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12(4) : 252-64.
Ribas A,Tumeh PC .2014 .The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res, 20(19) : 4982-4.
Mery CM,Pappas AN,Bueno R,Colson YL,Linden P,Sugarbaker DJ .2005 .Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest, 128(1) : 237-45.
Ribas A,Hu-Lieskovan S A .2016 .What does PD-L1 positive or negative mean. J Exp Med, 213(13) : 2835-40.
Ghosh C,Luong G,Sun Y. .2021 .A snapshot of the PD-1/PD-L1 pathway. J Cancer, 12(9) : 2735-46.
Chen YY,Wang LB,Zhu HL,Li XY,Zhu YP,Yin YL .2013 .Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin Med Sci J, 28(3) : 147-51.
Milovanovic IS,Stjepanovic M,Mitrovic D .2017 .Distribution patterns of the metastases of the lung carcinoma in relation to histological type of the primary tumor: an autopsy study. Ann Thorac Med, 12(3) : 191-8.
Chang YL,Yang CY,Huang YL,Wu CT,Yang PC .2017 .High PDL1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. Oncotarget, 8(11) : 18021-30.
Devesa SS,Bray F,Vizcaino AP,Parkin DM .2005 .International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer, 117(2) : 294-9.
Ma J,Chi D,Wang Y,Yan Y,Zhao S,Liu H .2018 .Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms. J Cancer, 9(19) : 3489-99.
Lin SY,Yang CY,Liao BC,Ho CC,Liao WY,Chen KY .2018 .Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: real-world data in Taiwan. J Cancer, 9(10) : 1813-20.
Igarashi T,Teramoto K,Ishida M,Hanaoka J,Daigo Y. .2016 .Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. ESMO Open, 1(4) : e000083.
Zhang M,Li G,Wang Y,Wang Y,Zhao S,Haihong P .2017 .PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep, 7(1) : 10255.
Miyazawa T,Marushima H,Saji H,Kojima K,Hoshikawa M,Takagi M .2019 .PD-L1 expression in non-small-cell lung cancer including various adenocarcinoma subtypes. Ann Thorac Cardiovasc Surg, 25(1) : 1-9.
Cooper WA,Tran T,Vilain RE,Madore J,Selinger CI,Kohonen-Corish M .2015 .PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 89(2) : 181-8.
Scheel AH,Ansén S,Schultheis AM,Scheffler M,Fischer RN,Michels S .2016 .PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations. Oncoimmunology, 5(5) : e1131379.
Lin G,Fan X,Zhu W,Huang C,Zhuang W,Xu H .2017 .Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget, 8(48) : 83986-94.
Remmele W,Stegner H .1987 .Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe, 8(3) : 138-40.
Takada K,Okamoto T,Shoji F,Shimokawa M,Akamine T,Takamori S .2016 .Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J Thorac Oncol, 11(11) : 1879-90.